EPI-589 Emerging Drug Insight and Market Forecast – 2032

EPI-589 Emerging Drug Insight and Market Forecast – 2032

“EPI-589 Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about EPI-589 for Amyotrophic Lateral Sclerosis in the 7MM. A detailed picture of the EPI-589 for Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the EPI-589 for Amyotrophic Lateral Sclerosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EPI-589 market forecast, analysis for Amyotrophic Lateral Sclerosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

EPI-589 ([R]-troloxamide quinone) is a novel, orally-administered small molecule being developed by PTC Therapeutics (acquired from BioElectron Technology Corporation) for adult neurodegenerative diseases in collaboration with Sumitomo Dainippon Pharma, who holds licensing rights for the compound in Japan and North America. EPI-589 targets oxidoreductase enzymes known to be critical to the regulation of inflammation and programmed cell death. EPI-589 is expected to show efficacy by removing the oxidative stress generated excessively by decreased mitochondrial function. It is expected to be developed for neurodegenerative indications arising through redox stress. The drug was granted Orphan Designation by the EMA for the treatment of ALS (EMA, 2017). A Phase IIa safety and biomarker study of EPI-589 in patients with ALS was completed in February 2018, and positive results were presented at the International Symposium on ALS and Motor Neuron Disease in December 2018. In Japan, DS Pharma completed the Phase I trial in 2021 and has initiated a Phase II trial in September 2021.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the EPI-589 description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.

Elaborated details on EPI-589 regulatory milestones and other development activities have been provided in this report.

The report also highlights the EPI-589 research and development activity in Amyotrophic Lateral Sclerosis details across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around EPI-589.

The report contains forecasted sales of EPI-589 for Amyotrophic Lateral Sclerosis till 2032.

Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.

The report also features the SWOT analysis with analyst views for EPI-589 in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EPI-589 Analytical Perspective by DelveInsight

In-depth EPI-589 Market Assessment

This report provides a detailed market assessment of EPI-589 in Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

EPI-589 Clinical Assessment

The report provides the clinical trials information of EPI-589 for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Amyotrophic Lateral Sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EPI-589 dominance.

Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to EPI-589 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EPI-589 in Amyotrophic Lateral Sclerosis.

Our in-depth analysis of the forecasted sales data of EPI-589 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EPI-589 in Amyotrophic Lateral Sclerosis.

Key Questions

What is the product type, route of administration and mechanism of action of EPI-589?

What is the clinical trial status of the study related to EPI-589 in Amyotrophic Lateral Sclerosis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EPI-589 development?

What are the key designations that have been granted to EPI-589 for Amyotrophic Lateral Sclerosis?

What is the forecasted market scenario of EPI-589 for Amyotrophic Lateral Sclerosis?

What are the forecasted sales of EPI-589 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Amyotrophic Lateral Sclerosis and how are they giving competition to EPI-589 for Amyotrophic Lateral Sclerosis?

Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?